Meda enters partnership for Elestrin in the US market

        Print
| Source: Meda AB
Meda has entered into a promotion agreement with Mission Pharmacal, a company
active in the women’s health area, for Meda’s topical estrogen replacement
therapy product Elestrin.

Elestrin was acquired in 2012 from Jazz Pharmaceuticals and has showed good
growth since then. Following the enhanced focus of Meda's US sales force on the
allergy and respiratory area, the promotion agreement is a right step that will
secure ongoing resources and continued growth for Elestrin.

"Through this partnership, we optimize sales efforts for Elestrin and at the
same time increase our focus on the respiratory area", said Dr. Jörg-Thomas
Dierks, CEO of Meda AB.
For further inquiries, please contact:

Paula Treutiger, Investor Relations                         ph: 46 733-666 599
paula.treutiger@meda.se
MEDA AB (publ) is a leading international specialty pharma company. Meda’s
products are sold in more than 120 countries worldwide and the company is
represented by its own organizations in over 55 countries. The Meda share is
listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm.
Find out more, visit www.meda.se.

Forward-looking Statements
This press release is not an offer to sell or a solicitation to buy shares in
Meda. This press release also contains certain forward-looking statements with
respect to certain future events and Meda’s potential financial performance.
These forward-looking statements can be identified by the fact that they do not
relate only to historical or current facts, and may sometimes include words such
as “may”, “will”, “seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”,
“forecast”, “believe” or other words of similar meaning. These forward looking
statements reflect the current expectations on future events of the management
at the time such statements are made, but are made subject to a number of risks
and uncertainties. In the event such risks or uncertainties materialize, Meda’s
results could be materially affected. The risks and uncertainties include, but
are not limited to, risks associated with the inherent uncertainty of
pharmaceutical research and product development, manufacturing and
commercialization, the impact of competitive products, patents, legal
challenges, government regulation and approval, Meda’s ability to secure new
products for commercialization and/or development and other risks and
uncertainties detailed from time to time in Meda AB’s interim or annual reports,
prospectuses or press releases. Listeners and readers are cautioned that no
forward-looking statement is a guarantee of future performance and that actual
result could differ materially from those contained in the forward-looking
statements. Meda does not intend, nor undertakes, to update any such forward
looking statements.